MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
12.37
+0.47 (3.95%)
Sep 10, 2026, 10:06 AM EDT - Market open
MiNK Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
63.12M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 64.09M |
| MindWalk Holdings | 11.43M |
| Apollomics | 8.84M |
| Seres Therapeutics | 1.88M |
| Hyperion DeFi | 1.40M |
| ImageneBio | 800.00K |
| Serina Therapeutics | 130.00K |
| Impact BioMedical | 35.00K |
INKT News
- 4 weeks ago - MiNK Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 4 weeks ago - MiNK Therapeutics Earnings release: Q2 2026 - Filings
- 4 weeks ago - MiNK Therapeutics Quarterly report: Q2 2026 - Filings
- 4 weeks ago - MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury - GlobeNewsWire
- 4 weeks ago - MiNK Therapeutics presents early observations from Phase 2 agenT-797 trial - TheFly
- 5 weeks ago - MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates - GlobeNewsWire
- 2 months ago - MiNK Therapeutics Transcript: AGM 2026 - Transcripts
- 3 months ago - MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting - GlobeNewsWire